Topalian Suzanne L, Sharpe Arlene H
Department of Surgery, Johns Hopkins University School of Medicine, Baltimore, MD 21287, USA.
Department of Microbiology and Immunobiology, Harvard Medical School, Boston, MA 02115, USA.
Immunity. 2014 Nov 20;41(5):682-4. doi: 10.1016/j.immuni.2014.11.005.
CTLA-4 is a key immune checkpoint in maintaining self-tolerance, which can be co-opted by cancer to evade immune attack. In Science, Kuehn et al. (2014) describe clinical manifestations from inherited heterozygous CTLA4 mutations, and some are reminiscent of immune-related consequences from anti-CTLA-4 cancer therapy.
细胞毒性T淋巴细胞相关抗原4（CTLA-4）是维持自身耐受的关键免疫检查点，癌症可利用该检查点逃避免疫攻击。在《科学》杂志上，库恩等人（2014年）描述了遗传性杂合CTLA4突变的临床表现，其中一些让人联想到抗CTLA-4癌症治疗产生的免疫相关后果。
